Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
April 17 2024 - 8:30AM
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical
company focused primarily on treatments for gastrointestinal (GI)
diseases with an emphasis on GIMOTI® (metoclopramide) nasal
spray, announced it will host a virtual KOL and investor webinar on
Wednesday, April 24 at 12:00 p.m. ET.
Moderated by Yale Jen, PhD, Senior Managing Director of Equity
Research at Laidlaw Capital Markets, the event will feature Michael
Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic
and prescriber of GIMOTI will provide his expert opinion and
insights on Evoke’s recently presented healthcare resource
utilization data, patient experience with GIMOTI and the rising
incidence of gastroparesis due to the increased use GLP-1 based
medications.
Participation Details:
Date: April 24, 2024
Registration: Link Available on Evoke IR site under Events
Time: 12:00 p.m. ET
Investors are encouraged to email dboateng@dkbpartners.net prior
to the event with queries.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on
the development of drugs to treat GI disorders and diseases. The
company developed, commercialized and markets GIMOTI, a nasal spray
formulation of metoclopramide, for the relief of symptoms
associated with acute and recurrent diabetic gastroparesis in
adults.
Diabetic gastroparesis is a GI disorder affecting millions of
patients worldwide, in which the stomach takes too long to empty
its contents resulting in serious GI symptoms as well as other
systemic complications. The gastric delay caused by gastroparesis
can compromise absorption of orally administered medications. Prior
to FDA approval to commercially market GIMOTI, metoclopramide was
only available in oral and injectable formulations and remains the
only drug currently approved in the United States to
treat gastroparesis.
Visit www.EvokePharma.com for more information.Follow
GIMOTI on FacebookFollow Evoke
Pharma on FacebookFollow Evoke
Pharma on LinkedInFollow Evoke
Pharma on Twitter
About Gimoti® (metoclopramide) nasal spray
GIMOTI is indicated for the relief of symptoms in adults with
acute and recurrent diabetic gastroparesis.
Important Safety Information
WARNING: TARDIVE DYSKINESIA
- Metoclopramide can cause tardive
dyskinesia (TD), a serious movement disorder that is often
irreversible. The risk of developing TD increases with duration of
treatment and total cumulative dosage.
- Discontinue GIMOTI in patients who
develop signs or symptoms of TD. In some patients, symptoms may
lessen or resolve after metoclopramide is stopped.
- Avoid treatment with metoclopramide
(all dosage forms and routes of administration) for longer than 12
weeks because of the increased risk of developing TD with
longer-term use.
GIMOTI is not recommended for use in:
- Pediatric patients due to the risk
of developing tardive dyskinesia (TD) and other extrapyramidal
symptoms as well as the risk of methemoglobinemia in neonates.
- Moderate or severe hepatic
impairment (Child-Pugh B or C), moderate or severe renal impairment
(creatinine clearance less than 60 mL/minute), and patients
concurrently using strong CYP2D6 inhibitors due to the risk of
increased drug exposure and adverse reactions.
GIMOTI is contraindicated:
- In patients with a history of
tardive dyskinesia (TD) or a dystonic reaction to
metoclopramide.
- When stimulation of gastrointestinal
motility might be dangerous (e.g., in the presence of
gastrointestinal hemorrhage mechanical obstruction, or
perforation).
- In patients with pheochromocytoma or
other catecholamine-releasing paragangliomas. Metoclopramide may
cause a hypertensive/pheochromocytoma crisis, probably due to
release of catecholamines from the tumor.
- In patients with epilepsy.
Metoclopramide may increase the frequency and severity of
seizures.
- In patients with hypersensitivity to
metoclopramide. Reactions have included laryngeal and glossal
angioedema and bronchospasm.
Potential adverse reactions associated with metoclopramide
include: Tardive dyskinesia (TD), other extrapyramidal effects
(EPS), parkinsonism symptoms, motor restlessness, neuroleptic
malignant syndrome (NMS), depression, suicidal ideation and
suicide, hypertension, fluid retention, hyperprolactinemia, effects
on the ability to drive and operate machinery. Most common adverse
reactions (≥5%) for GIMOTI are: dysgeusia, headache, and fatigue.
These are not all of the possible side effects of GIMOTI. Call your
doctor for medical advice about whether you should take GIMOTI and
the possible risk factors and side effects. You are encouraged to
report negative side effects of prescription drugs to the
FDA.Visit www.fda.gov/medwatch or call
1-800-FDA-1088.
Safe Harbor Statement
Evoke cautions you that statements included in this press
release that are not a description of historical facts are
forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplates,” “believes,” “estimates,”
“predicts,” “potential” or “continue” or the negatives of these
terms or other similar expressions. These statements are based on
the company’s current beliefs and expectations. These
forward-looking statements include statements regarding: planned
leadership changes and Evoke’s commercialization plans. The
inclusion of forward-looking statements should not be regarded as a
representation by Evoke that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Evoke’s
business, including, without limitation: risks associated with
timely and successfully executing a smooth transition of the chief
executive functions; risks and uncertainties related to management
changes; Evoke’s and EVERSANA’s ability to successfully drive
market demand for GIMOTI; Evoke’s ability to obtain additional
financing as needed to support its operations; Evoke may use its
capital resources sooner than expected; Evoke’s dependence on third
parties for the manufacture of GIMOTI; Evoke is entirely dependent
on the success of GIMOTI; inadequate efficacy or unexpected adverse
side effects relating to GIMOTI that could result in recalls or
product liability claims; Evoke’s ability to maintain intellectual
property protection for GIMOTI; and other risks and uncertainties
detailed in Evoke’s prior press releases and in the periodic
reports it files with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and Evoke undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof.
All forward-looking statements are qualified in their entirety by
this cautionary statement. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Investor & Media Contact:Daniel
Kontoh-BoatengDKB PartnersTel:
862-213-1398dboateng@dkbpartners.net
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Apr 2023 to Apr 2024